Masimo Corporation
MASI · Price history
Company & revenue
About Masimo Corporation
Primary reporting period: 2026-01-03 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions.
How they make money
Masimo generates revenue primarily through the development, manufacture, and marketing of noninvasive patient monitoring technologies and hospital automation solutions. The business model relies on a high percentage of recurring revenue derived from the sale of single-patient-use sensors and disposables, which are used in conjunction with their installed base of monitoring devices sold to hospitals and alternate care facilities.
Products & services
Masimo offers patient monitoring technologies including Masimo SET pulse oximetry, rainbow SET Pulse CO-Oximetry, brain function and hemodynamic monitoring, and the Masimo Hospital Automation platform (Patient SafetyNet, Iris, iSirona, Replica, and UniView).
Brands & revenue mix
Core pulse oximetry technology platform.
Separate brand revenue is not available in this research.Source
Noninvasive monitoring platform for multiple blood constituents.
Separate brand revenue is not available in this research.Source
Suite of connectivity and automation solutions including Patient SafetyNet.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2026-01-03Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2026-01-03Source
Period ended 2026-01-03Source
Period ended 2026-01-03Source
Period ended 2026-01-03Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturers — The company utilizes various third-party contract manufacturers for the production of components and finished goods.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
31
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
63
Fair
Financial Strength
81
Business Quality / Moat
52
Management
88
Growth Quality
22
Risk / Durability
47
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
26
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
33/100
Building Historical Record
Model Score 33/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for MASI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MASI maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is MASI's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is MASI's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify MASI's current valuation?
Essential Investment Snapshot
Wall Street Score
31
Opportunity Score
26
Market Cap
$9.42B
P/E Ratio
125.0
EPS
$1.44
52-Week High
$179.99
52-Week Low
$125.94
Beta
1.18
Intrinsic Value
$12.24
Analyst Target
$180.00
Shares Outstanding
54.2M
Total Revenue
$1.56B
Total Debt
$485.9M
Dividend
No current dividend
Liquidation Value / Share
$14.56
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for MASI
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on MASI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +High recurring revenue model from sensor and disposable sales.
- +Large installed base of monitoring technology.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on third-party contract manufacturers.
- −Intense competition in the medical device industry.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
31
Oct 1, 2026
Change
Unchanged
Current Score
31
Oct 5, 2026
Category Changes
MASI score was unchanged.
Projected Score
Projected Score
34
Projected Change
+2.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$179.95
Model Intrinsic Value
$12.24
Difference
+$167.71
+1370.2% vs IV
Margin of Safety
-1370.2%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56B | $1.53B | $2.09B | $2.05B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $596.5M | $581.7M | $1.09B | $1.04B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $962.0M | $945.2M | $1.00B | $1.00B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $122.5M | $126.4M | $222.8M | $175.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $530.0M | $506.0M | $743.8M | $664.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $652.6M | $632.4M | $1.27B | $867.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $344.5M | $344.6M | -$158.7M | $236.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $309.4M | $312.8M | -$266.7M | $136.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $30.6M | $33.2M | $43.6M | $50.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $275.6M | $272.6M | -$305.3M | $88.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $58.8M | $64.9M | -$400K | $6.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $76.3M | -$151.5M | -$304.9M | $81.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.44 | $-2.83 | $-5.72 | $1.54 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 52.20M | 53.60M | 53.30M | 52.80M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 52.60M | 54.20M | 53.30M | 54.10M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$403.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$1.09
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-28.7%
Cash Change
-4.7%
Margin Change
+60.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 8.5%. EPS declined 134.4%. Cash declined 4.7%. Total debt declined 28.7%. Net income margin improved by 60.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
No news available for MASI.
Rumor Mill · MASI
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial